Biohaven Q2 FY26 net loss narrows 30.7% to $137.31 million; R&D expenses fall 45.34% to $100.81 million

• Biohaven posted a GAAP net loss of USD 137.31 million, or USD 0.91 a share, narrowing from USD 198.15 million, or USD 1.94 a year earlier.
• R&D expense fell 45.34% to USD 100.81 million, attributed to lower direct program and preclinical spend following a 4Q 2025 reprioritization.
• Other expense swung to USD 12.02 million from other income of USD 13.82 million on higher non-cash fair-value losses tied to notes payable.
• Cash, cash equivalents, marketable securities and restricted cash totaled about USD 270.5 million at June 30, 2026.
• Pipeline milestones include a Phase 3 start for BHV-1300 in Graves’ disease; opakalim Phase 2/3 RISE3 topline data remains on track for 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608101602PR_NEWS_USPR_____NE22668) on August 10, 2026, and is solely responsible for the information contained therein.